title: Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies.
abstract: Substitute methadone prescribing is one of the main modes of treatment for opioid dependence with established evidence for improved health and social outcomes. However, the pharmacology underpinning the effects of methadone is little studied despite controversies about dosing in relation to outcome. We therefore examined the relationship between methadone dose and occupation of opioid receptors in brain using the positron emission tomography (PET) radioligand [(11)C]diprenorphine in humans and rats. Eight opioid-dependent subjects stable on their substitute methadone (18-90 mg daily) had an [(11)C]diprenorphine PET scan at predicted peak plasma levels of methadone. These were compared with eight healthy controls. No difference in [(11)C]diprenorphine binding was found between the groups, with no relationship between methadone dose and occupancy. Adult male Sprague-Dawley rats that had been given an acute i.v. injection of methadone hydrochloride (0.35, 0.5, 0.7, or 1.0 mg kg(-1)) before [(11)C]diprenorphine showed a dose-dependent increase in biodistribution but no reduction in [(11)C]diprenorphine binding. We suggest that the lack of a dose-dependent relationship between methadone dose, either given chronically in human or acutely in rat, and occupancy of opioid receptor measured with [(11)C]diprenorphine PET is related to efficacy of this opioid agonist at very low levels of opioid receptor occupancy. This has implications for understanding the actions of methadone in comparison with other opioid drugs such as partial agonists and antagonists.
authors.affiliation: Psychopharmacology Unit, University of Bristol, Whitson St., Bristol, BS1 3NY, UK.
authors.forename: Jan K
authors.initials: JK
authors.lastname: Melichar
authors.forename: Susan P
authors.initials: SP
authors.lastname: Hume
authors.forename: Tim M
authors.initials: TM
authors.lastname: Williams
authors.forename: Mark R C
authors.initials: MR
authors.lastname: Daglish
authors.forename: Lindsay G
authors.initials: LG
authors.lastname: Taylor
authors.forename: Rabia
authors.initials: R
authors.lastname: Ahmad
authors.forename: Andrea L
authors.initials: AL
authors.lastname: Malizia
authors.forename: David J
authors.initials: DJ
authors.lastname: Brooks
authors.forename: Judith S
authors.initials: JS
authors.lastname: Myles
authors.forename: Anne
authors.initials: A
authors.lastname: Lingford-Hughes
authors.forename: David J
authors.initials: DJ
authors.lastname: Nutt
mesh_terms: D000328:Adult; D000818:Animals; D016739:Behavior, Addictive; D002250:Carbon Radioisotopes; D004174:Diprenorphine / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008691:Methadone / Q000494:pharmacology*; D008875:Middle Aged; D009293:Opioid-Related Disorders / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid / Q000378:metabolism*; D013997:Time Factors
chemical_list: D002250:Carbon Radioisotopes; D011957:Receptors, Opioid; D004174:Diprenorphine; D008691:Methadone